BACKGROUND: Lymphoma incidence is increased among human immunodeficiency virus (HIV)-infected individuals soon after antiretroviral therapy (ART), perhaps due to unmasking immune reconstitution inflammatory syndrome (IRIS). Clinical characteristics and survival for unmasking lymphoma IRIS have not been described. METHODS: We studied lymphoma patients in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) from 1996 until 2011. Unmasking lymphoma IRIS was defined as lymphoma within 6 months after ART accompanied by a ≥ 0.5 log10 copies/mL HIV RNA reduction. Differences in presentation and survival were examined between IRIS and non-IRIS cases. RESULTS: Of 482 lymphoma patients, 56 (12%) met criteria for unmasking lymphoma IRIS. Of these, 12 (21%) had Hodgkin lymphoma, 22 (39%) diffuse large B-cell lymphoma, 5 (9%) Burkitt lymphoma, 10 (18%) primary central nervous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma. Median CD4 cell count at lymphoma diagnosis among IRIS cases was 173 cells/µL (interquartile range, 73-302), and 48% had suppressed HIV RNA <400 copies/mL. IRIS cases were similar overall to non-IRIS cases in histologic distribution and clinical characteristics, excepting more frequent hepatitis B and C (30% vs 19%, P = .05), and lower HIV RNA at lymphoma diagnosis resulting from the IRIS case definition. Overall survival at 5 years was similar between IRIS (49%; 95% confidence interval [CI], 37%-64%) and non-IRIS (44%; 95% CI, 39%-50%), although increased early mortality was suggested among IRIS cases. CONCLUSIONS: In a large HIV-associated lymphoma cohort, 12% of patients met a uniformly applied unmasking lymphoma IRIS case definition. Detailed studies of lymphoma IRIS might identify immunologic mechanisms of lymphoma control.
BACKGROUND:Lymphoma incidence is increased among human immunodeficiency virus (HIV)-infected individuals soon after antiretroviral therapy (ART), perhaps due to unmasking immune reconstitution inflammatory syndrome (IRIS). Clinical characteristics and survival for unmasking lymphoma IRIS have not been described. METHODS: We studied lymphomapatients in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) from 1996 until 2011. Unmasking lymphoma IRIS was defined as lymphoma within 6 months after ART accompanied by a ≥ 0.5 log10 copies/mL HIV RNA reduction. Differences in presentation and survival were examined between IRIS and non-IRIS cases. RESULTS: Of 482 lymphomapatients, 56 (12%) met criteria for unmasking lymphoma IRIS. Of these, 12 (21%) had Hodgkin lymphoma, 22 (39%) diffuse large B-cell lymphoma, 5 (9%) Burkitt lymphoma, 10 (18%) primary central nervous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma. Median CD4 cell count at lymphoma diagnosis among IRIS cases was 173 cells/µL (interquartile range, 73-302), and 48% had suppressed HIV RNA <400 copies/mL. IRIS cases were similar overall to non-IRIS cases in histologic distribution and clinical characteristics, excepting more frequent hepatitis B and C (30% vs 19%, P = .05), and lower HIV RNA at lymphoma diagnosis resulting from the IRIS case definition. Overall survival at 5 years was similar between IRIS (49%; 95% confidence interval [CI], 37%-64%) and non-IRIS (44%; 95% CI, 39%-50%), although increased early mortality was suggested among IRIS cases. CONCLUSIONS: In a large HIV-associated lymphoma cohort, 12% of patients met a uniformly applied unmasking lymphoma IRIS case definition. Detailed studies of lymphoma IRIS might identify immunologic mechanisms of lymphoma control.
Authors: B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch Journal: Science Date: 1997-07-04 Impact factor: 47.728
Authors: M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: D W Notermans; N G Pakker; D Hamann; N A Foudraine; R H Kauffmann; P L Meenhorst; J Goudsmit; M T Roos; P T Schellekens; F Miedema; S A Danner Journal: J Infect Dis Date: 1999-10 Impact factor: 5.226
Authors: Silvia Montoto; Jamie Wilson; Kate Shaw; Maureen Heath; Andy Wilson; Christopher McNamara; Chloe Orkin; Mark Nelson; Margaret Johnson; Mark Bower; Kate Cwynarski Journal: AIDS Date: 2010-03-27 Impact factor: 4.177
Authors: Lindsay M Morton; Clara J Kim; Lawrence M Weiss; Kishor Bhatia; Myles Cockburn; Debra Hawes; Sophia S Wang; Cindy Chang; Sean F Altekruse; Eric A Engels; Wendy Cozen Journal: Leuk Lymphoma Date: 2013-07-29
Authors: M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler Journal: J Infect Dis Date: 1998-07 Impact factor: 5.226
Authors: Graeme Meintjes; Stephen D Lawn; Fabio Scano; Gary Maartens; Martyn A French; William Worodria; Julian H Elliott; David Murdoch; Robert J Wilkinson; Catherine Seyler; Laurence John; Maarten Schim van der Loeff; Peter Reiss; Lut Lynen; Edward N Janoff; Charles Gilks; Robert Colebunders Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: Emilio Letang; James J Lewis; Mark Bower; Anisa Mosam; Margareth Borok; Thomas B Campbell; Denise Naniche; Tom Newsom-Davis; Fahmida Shaik; Suzanne Fiorillo; Jose M Miro; David Schellenberg; Philippa J Easterbrook Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: Michalina A Montaño; Maganizo B Chagomerana; Margaret Borok; Matthew Painschab; Thomas S Uldrick; Rachel A Bender Ignacio Journal: Curr HIV/AIDS Rep Date: 2021-02-02 Impact factor: 5.071
Authors: Katherine D Westmoreland; Christopher C Stanley; Nathan D Montgomery; Bongani Kaimila; Edwards Kasonkanji; Nader Kim El-Mallawany; Peter Wasswa; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Maria Chikasema; Victor Makwakwa; Coxcilly Kampani; Bal M Dhungel; Marcia K Sanders; Robert Krysiak; Tamiwe Tomoka; N George Liomba; Dirk P Dittmer; Yuri Fedoriw; Satish Gopal Journal: Pediatr Blood Cancer Date: 2016-10-26 Impact factor: 3.167
Authors: Matthew S Painschab; Edwards Kasonkanji; Takondwa Zuze; Bongani Kaimila; Tamiwe Tomoka; Richard Nyasosela; Ruth Nyirenda; Bal M Dhungel; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Wilberforce Mhango; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Thomas C Shea; Nathan D Montgomery; Yuri Fedoriw; Satish Gopal Journal: Br J Haematol Date: 2018-11-18 Impact factor: 6.998